Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381862 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
A Phase 2 study of Colorectal Cancer and Nausea and Vomiting, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 6
- Study locations
NCT00381862 is a Phase 2 study of Colorectal Cancer and Nausea and Vomiting that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 54 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT00381862, a Phase 2 study of Colorectal Cancer and Nausea and Vomiting, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 6
- Study locations
Study Summary
RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused by chemotherapy in patients receiving chemotherapy for metastatic colorectal cancer.
Conditions Studied
Interventions
- DRUG dexamethasone
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG irinotecan hydrochloride
- DRUG aprepitant
Study Locations (6)
Georgia
- St. Josephs/Cander Hospital - Savannah
Hawaii
- Kaiser Permanente - Hilo
Illinois
- Ingalls Memorial Hospital - Harvey
Missouri
- Kansas City Cancer Center - Kansas City
Oregon
- OHSU Knight Cancer Institute - Portland
Texas
- Texas A & M university / Scott and White Clinic - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381862
The ClinicalTrials.gov registry entry for NCT00381862 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (96% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which dexamethasone is the first listed.
NCT00381862 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Georgia, Hawaii, Illinois.
Frequently Asked Questions
What is clinical trial NCT00381862 about?
NCT00381862 is a clinical study titled "Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX". RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused b...
What is the current status of trial NCT00381862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2006-06. Estimated completion is 2008-07.
What conditions does trial NCT00381862 study?
This clinical trial studies the following conditions: Colorectal Cancer, Nausea and Vomiting.
What interventions are being tested in trial NCT00381862?
The interventions under investigation include: dexamethasone (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), irinotecan hydrochloride (DRUG), aprepitant (DRUG).
Who is sponsoring clinical trial NCT00381862?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00381862 being conducted?
This trial has 6 study locations across Georgia, Hawaii, Illinois, Missouri, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.